“…The most interesting finding from this study was that ether phospholipids in plasma showed significantly greater incorporation of EPA and DHA following KO than FO treatment. We propose that ether phospholipids present in the KO contributed to increased ether phospholipid concentrations in plasma, since circulating plasmalogens are either derived from dietary sources and/or are synthesized in the liver and gastrointestinal epithelium (Roels et al, 1987, Astarita et al, 2010, Paul et al, 2021. In the present study, alkyl-phosphatidylcholine (PakCho) and lyso-PakCho were the main species detected in the KO supplement, accounting for 7% of the choline phospholipids, with PC(O-36:5), PC(O-16:0-22:6), LPC(O-16:1), LPC(O-18:1), and PC(O-32:1) accounting for 6% (Sung et al, 2019).…”